Endurant Capital Management LP Akari Therapeutics PLC Transaction History

Endurant Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$1.81 - $3.88 $373,875 - $801,456	-206,561 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.5 - $2.02 $309,841 - $417,253	206,561 New	206,561 $382,000
Q4 2018 Feb 14, 2019	SELL	$1.57 - $2.49 $256,866 - $407,386	-163,609 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$1.82 - $2.56 $30,372 - $42,721	-16,688 Reduced 9.26%	163,609 $419,000
Q2 2018 Aug 14, 2018	SELL	$1.77 - $2.28 $30,444 - $39,216	-17,200 Reduced 8.71%	180,297 $352,000
Q1 2018 May 15, 2018	SELL	$1.77 - $4.39 $6,372 - $15,803	-3,600 Reduced 1.79%	197,497 $359,000
Q4 2017 Feb 14, 2018	BUY	$4.08 - $7.4 $820,475 - $1.49 Million	201,097	201,097 $871,000

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $77.7M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.